25
Feb

More than three years after the FDA sent InterMune back to the clinic for another Phase III study of its lung drug pirfenidone–Esbriet–for idiopathic pulmonary fibrosis, the biotech says it scored a win on the primary as well as two secondary endpoints for the lung-scarring treatment. And now InterMune says it’s ready to go back to the FDA and lay out the data, hoping for an approval that will greatly expand the market for a drug now sold in Europe.

…read more

Source: UPDATED: InterMune rockets up after scoring a big win on PhIII lung drug study

    

0 No comments